BAJAJ HEALTHGARE LIMITED

Date: 29/01/2021,

To,

The Manager Listing Compliance Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001.

Dear Sir/Madam,

Ref:

Sub:

Script Id "BAJAJHCARE", Script Code "539872",

Outcome of Board Meeting

unaudited financial result

held on 29th January,

for the Quarter ended

2021 & Submission

December 31, 2020.

of revised

This is with reference to our earlier communication for "Outcome

January, 2021 & Submission of financial result" dated January

of Board

29, 2021,

Meeting held on 29th

we hereby submit a

tprrhereasevtu,ivlsiteotduhesarluernqeauaaaudrrdeytietnreso duib.cem.hfiait3nn0tag%enedciSaeilnptto,tdrh2eaes0yu2l0ftitghwufe.rorrree.st thwPrearesopQvouirastarineotdneorvffoeorrersntidthgaeixhrdtdanDq/deuacEtreaytmerpbrnoeigrnragas p3hwP1ie,elcrla2l0S2ha0sa.reern.riPonlreeWaesmienofnufntriohtgthsueerrerisnesstuatflthoteer

ended on 31st December,2020.

We herewith again resubmit the full set of rectified result along with Limited Review Report. Inconvenience caused to you is highly regretted. Request you to take the above on records. Thanking you,

Yours faithfully,

For and on behalf of Board of Directors

of Bajaj Healthcare Limited

Mr. Aakash Keshari Company Secretary Encl: a/a

Regi.stered

Offisnace

: 602-B6ND. 06,

Bhoomi

Velocitity y

IInnffootech

Park,

Plot?

NToe.l. B:-+399,1

B2-239/6A6,17 B-734900A/1-,49R9oa?d

BAJAJ HEALTHGARE LIMITED FNaox.: 23+, 91Wag22le66I1nd7.74E5s8tate, WeTbhsaintee(We:swtw)w,.baTjhaajnhee-a4l0t0h.6c0o4m.

Date: 29/01/2021.

To,

The Manager Listing Compliance Department, BSE Limited, Phiroze Jeejeebhoy Towers,

Dalal Street, Fort,

Mumbai - 400 001. Dear Sir/Madam, Ref: Script Id "BAJAJHCARE", Script Code "539872".

Sub: Outcome of Board Meeting held on 29` January, 2021 & Submission of financial result.

We hereby inform you that at the meeting of the Board of Directors of our Company held today i.e, 29% January, 2021 has considered and approved the following:

>?

Unaudited

2020 along

Standalone Financial result

Limited Review Report.

for

the

Quarter

/ Nine

months

ended

on

31st

December,

>?

Company has planned to enter Generic Market in a phased manner. This will cover all major dermatological range of products. The revenue in first quarter of FY 2021-22.

and have identified several products to launch therapeutic segments like Chronic, acute and from generic market are expected to generate

We wish to

02.15 PM.

inform

you

that

Board

Meeting

commenced

today

at 12.30

p.m.

and

concluded

at

We are enclosing herewith the copy of financial result.

Thanking you,

Yours faithfully,

For and on behalf of Board of Directors

of Bajaj Healthcare Limited

c

Mr. Aakash Keshari Company Secretary Encl: a/a

BAJAJ HEALTHCARE LIMITED

Registered Office : 602-606, Bhoomi Velocity Infotech Park, Plot No. B-39, B-39/A, B-39 A/1, Road No. 23, Wagle Ind. Estate, Thane(West), Thane-400 604. ? Tel. : + 91 22 6617 7400 - 499 ? Fax : + 91 22 66177458 ? Website :

b o

Chaturvedi & Agrawal

Chartered Accountants

Independent Auditor's Review Report on Financial Results of the Company Pursuant Disclosure Requirements) Regulations, 2015,

the to

Quarterly and the Regulation 33

Year of the

to Date SEBI

Unaudited Standalone (Listing Obligations and

as amended

Review Report to The Board of Directors Bajaj Healthcare Limited

1.

ALCRWpleeoreqmiaullpitharhanecv1ay,mereen2pt0rus2eLr)0visimuieaRtwtneoeetgddu(Dlttaoehttcehiteehomen"bsCa,ercoercqm2uop0ima13rp51ne,,aymn"eya)n2sit0ns2ag0fmoorefn(sdttRthheaeeedtgeumql"(ueaStantthrtieatotener"omLfei3esn3tntuid"nnoe)agfdudtRhiaeDettgeteuadcSlceEahBmteIsbidtoeanr(nshLd.eiars3let1ow,ininetg2h,0O2fb0ilnbiaegnaiacnntidgailoynessaurrbesmaunitldtottseDddiasotfcelbyoBsfaurjtroahemje

TpACiehrsxSoiispmsnurpcee3idas4psn"Sl)tyetah'satesrepcemrloaeeniBnscduotclna,rudrdisedboirewowdnnhoaifnucdonhiDnndierotraethipchsepteSolreSrithcstcet,aaaicbtolcehnreomaeuessnnp1Itto3nbi3ndensibegiaanobnsfielppdtirAhrtieceynocpcnaoiCrpuooelonfmeudtprsiatnhnirgnegeievenaiseCScertcwoa.aomlAnrcplddtya,aannryacd2'ces0cs31e43wpittMe"ahsdaInntataiehmngereienmImrdneeedcidnFao,it.gnnainrOtecuaiairnodadnl

approved by the

and measurement Reporting" ("Ind with relevant rules responsibility is to

3.

pos(EWpmpninreiSeegtotsrRnicssfEAiteoto)ufycdnardi"oustmicnreat2deimni4sustern1t.csne0ghuttse,mee.paAddaotnnrt"dsreebRAiyevroebusvicvrleitoriewehtneeewhrvswaeietfItveqioonsiwrusmoetefiswinoguftbtobhuiItflsttnnoayetatfianeinncbrnoettidifthaiomeelmaeirClosdihldeSmFayneatinrtnranotidattalffeenteiirscmneeeseaiadendacnnalcictbniiaoAnlasueclssInaiccunntnoorufipusiaonaeannnrguctcftdmcoeaoitaotrnht.mromatiadbnasoattaAtsntancieaiccoornntefonsoP,reaIdaurnsiwwdcdfisniahoiottungnaehrr.dsltmiayhcsne,eTottcdahhrnseepidwspuelbctotSyyhhftstiaetdeatnoadntgmnhdwaSedanetkaiornaaritdIndtnwaneageoldmcxoyureecnptelpnoirqdietrceunnRadsiqldesarubeeivniessrnciaciateeneonfwstdmrh,aeaAweuetiudEtodiphntiwtarohgetwifeaoamSorrgratppmreeialainanmrtlonideeefoyoavrnfnriiat.tdeanashsowldlelf

4.

LAgtBlchiaeaietsnsd,teeiradnadcg2loc0lowoy1nRn3mepgoaauuicrlnancsayettrpiihetaneovemgnidesaen,fwdSoietnriaedcntso,Iceannlimdduideuadrnc,eittanI,denghddaipstawrhniaeestnphoaAatmrcbaeocrnddveonieluse,encirvntlaoinnsaotninetcgdhciwornhurStlgidtheceaashnnhdcaisaeinirtsfdscoisuwsoreimmdttaehsotpietbtotcheohnieefroideueirrurdseencqcdluaoeouitgrsntrnedeeidnedt,traiinootdnonoSrecbtoattehnthiaadhtotednricmisatecu1alacs3cos3oecsnsueotrduaoefunismntiseitnhtnneogttaenbCryeompplrrismmiiepannvatcceoneiifrppiitllethaeehsalsset

misstatement.

For Chaturvedi & Agrawal

Chartered Accountants

FRN: 101717W

Rasik Chaturvedi M. no: 039524

UDIN: 210395244 AAAAD1508

Date: January 29, 2021

Place; Thane

Head Office : 724, Ecstasy, City of Joy, JSD Road, Near Station, Mulund (W), Mumbai--- 400 080

Cell: 9867032901; Email:rasik@.in / rasikchaturvedi@

A

( /\ |

UNAUDITED

FINANCIAL

RESULTS

BAJAJ HEALTHCARE LIMITED (CIN No. : L99999MH1993PLC072892 ) FOR THE QUARTER AND NINE MONTH

ENDED ON 31st DECEMBER , 2020 (Rs. In Lakhs Except for Earnings

Per Shai)

I. Revenue from operations

Il, Other Income

HI. Total Revenue (I+)

IV. Expenses (a) Cost of materials consumed (Including Other Direct Expenses)

(b) Changes in Inventories of Finished Good (c) Employee benefits expense (d) Finance Costs (d) Depreciation and amortisation expense

(ec) Other expenses

Total Expenses

V. Profit before Exceptional Items VI. Exceptional items

VIL. Profit before Extra Ordinary Items

VILL Extra Ordinary items VIL Profit Before Tax VIII. Tax Expense (a) Current tax (b) Deferred Tax

(c) Earlier Years Total Tax Expenses

IX. Profit (Loss) for the Period

X. Other comprehensive Income (i) Items that will not be reclassified to profit or loss (ii) Income tax relating to items that will not be reclassified to profit or loss (iii) Items that will be reclassified to profit or loss (iv) Income tax relating to items that will be reclassified to profit or loss

Total Comprehensive Income for the Period

XI. Paid-up Equity Share Capital (Face Value Rs. 10/-)

XII. Other Equity excluding Revaluation Reserve

XII. EPS (Not Annualised)

(a) Basic (in Rs.) (b) Diluted (in Rs.)

Dividend Declared during the Year: Interim Dividend (Per Share) Special Dividend (Per Share)

Cumulative Dividend Percentage

Vear Ended

--[ Sh2.0

of

31.12.2019| 31.03.2020|

(Unaudited) | (Unaudited) | (Unaudited) { (Unaudited) | (Unaudited) | (Audited)

17,833.44 | 20,663.47

176.35

209.49

18,009.79 | 20,872.96

9,927.23

12.30 9,939.53

52,480.23 | 29,151.18]

41,000.84

476.02

31.82

317.91

52,956.25 | 29,183.00 | 41,318.74

11,802.07}

314.14 871.16 192.41 395,53

440.81

14,016.12 |

15,423.60)

191.66 980.37 217.18 397.54

836.97

18,047.32

3,993.67 -

3,993.67

3,993.67

2,825.64 -

2,825.64

2,825.64

1,400.00 -48.61

-

1,351.39

2,642.28

826.60 -12.63

-

813.97

2,011.67

7,671.45

-114.43 674.44 165.49 285.17

358.96

5,041.08

898.45 -

898.45

898.45

290.00 -11.41

0.31 278.90

619.55

37,614.06 |

130.12 2,650.26

614.41 ?(1,169.54

1,915.08

44,093.48 |

23,062.12}

-141.03 2,083.01

505.59 874.54

985.12

27,369.35 |

32,027.10

-508.76 2,817.83

644,93 1,212.33

1,519.28

37,712.73

8,862.77 -

8,862.77

8,862.77

1,813.65 -

1,813.65

1,813.65

3,606.02 -

3,606.02

3,606.02

2,800.00 -120.34

-

2,679.66

6,183.11

540.00 -14.43

20.82

546.39

1,267.26

910.00 148.91

23.44

1,082.35

2,523.67

-

2,642.28

1,379.92

-

19.15 19.15

1.25 0.50

17.50%

-

2,011.67

1,379.92

-

14.58 14.58

-

-

-

619.55

1,379.92

-

4.49 4.49

-

-

-

6,183.11

1,379.92

-

44.81 44.81

1.25 0.50

17.50%

-

1,267.26

1,379.92

-

918 9.18

-

-

-25,.51

-

2,498.16

1,379.92

16,405.88

18.29 18.29

-

-

Note : a) The above

Financial

Results

have

been

reviewed

by

the

Audit

Committee

and

subsequently

approved

by

Board

of Directors

at their

respective

meetings

held

on

January 29, 2021.

b) As April,

the Company 2020. Hence,

was the

listed in SME segment of BSE Ltd as on company has adopted Indian Accounting

3 Ist March 2019 and migrated to Main Board Standard ("Ind AS") as notified under Section

on 29th May 2019, Ind-AS 133 of the Companies Act,

is applicable from Ist 2013 ("the Act") read

with the Companies (indian Accounting Standards) Rules, 2015 for first time from April 1, 2020. The above financial results have been prepared in accordance

with principles as laid down in Ind AS-34 - Interim Financial Reporting.

?) The financial Company. The reflects true and End figures for

results for the Quarter and Nine Month ended 31st restated comparative figures under IND -AS prepared fair view of Company's affairs in Indian Accounting 31st March 2020 and are not subject to Review of the

December 2020 have been subjected to limited review by the by the Management are after exercising necessary due diligence Standard ("Ind AS") for Quarter and Nine Month ended 3tst Statutory Auditors. The financial results for such period prepared

statutory auditors of the to ensure financial results December 2019 and Year under IGAAP framework

were reviewed by Statutory Auditors, d) Reconciliation of Net profit and Reserves as reported under generally accepted accounting principles (GAAP) and as per IND AS is given below:

(Rs. in Lakhs)

Net profit afier tax/ Reserve reported under previous GAAP

Adjui stments iinnccrreeaassiing/(decreeaassiing) net pro, fit/ Rese5 rve as r; eported ii n the

previous GAAP Adjustments in Deferred Tax Fair Value/ Revalued figure considered as Deemed Cost for Land under Property Plant and Equipment as on 01st April 2019 Net Profit after tax/ Reserve reported under Ind AS Other Comprehensive Income / Loss (Net of Tax) Total Comprehensive Income (after tax)/ Reserves as reported under

Ind AS

~24.94

6.48 -

619.55 -

619.55

30.63

7.96 -

1267.26 -

1267.26

2249.98

360.89

-87.20 -

2523.67 -25.51

2498.16

139.96

38.85

2751.79 16431.39

-25.51

16405.88

ce) The Statement as per IND AS - 108 on segment reporting is given as Annexure-A. f) Figures of previous period have been regrouped/reclassified, wherever necessary, to make them comparable and to conform with current period classification.

.

Date: 29th January 2021 Place: Thane

---- we

By Order of the Board For Bajaj Healthcare Limited

eae

I . G ew va \

Mr. Sajankumar R Bajaj

D.No.: 00225950 Chairman and Managing Director

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download